суббота, 26 апреля 2008 г.

Life science briefing: Fri, Apr 11, 2008



TODAY'S HEADLINES:


Xytis acquires USD 15M for brain-injury drugs
(VentureWire)
Symptomatic maker Fleur Biotechnology plans to go public, launch breast-cancer test
(Edgar)
RiverVest Venture Partners brings up USD 75M life science fund
(release)


Note: I'm a small lamentable to denote that this will be my last life science briefing at VentureBeat, although with portion, it wo not be the terminal of my time here. Getting down Monday, I'll be blogging on a regular basis on the drug manufacture and health care all over at BNET Manufactures, a fresh CNET venture, so drop by if you can. (Fixing for that move is the main reason non-briefing posts have been scarce lately.) I still hope to place here now and then as good, since natural covering below-the-radar inaugurations has been a clap, and I'm not ready to afford it up rather up to now.



It's been an outstanding twelvemonth - my first VentureBeat post was on April 3, 2007 - and I want to give thanks Matt for the chance to fall in you here, and all our regular subscribers and commenters for your time and your penetrations. As diarists, we're only as full as our root and subscribers, and you guys have assisted in innumerous shipways to get me look very much voguish than I genuinely am. -D.P.H.]


Stent maker IDev Technical school lifts USD 25M -IDev Engineerings, a Houston medical-device inauguration, brocaded USD 25 000 000 in an one funding round, VentureWire reports. The company is germinating a fresh eccentric of stent for use in shoring up open the liver's gall channels .


The company's existent investors, a grouping that admits Embayment Metropolis Capital, Hero Capital, PTB Scientific disciplines and RiverVest Venture Partners, furnished the funding. IDev held antecedently brocaded USD 24 000 000, consorting to VW.


Xytis acquires USD 15M for brain-injury drugs - Irvine, Khalif.-based Xytis, a biotech focussed on disorders of the central unquiet scheme, embossed USD 15 000 000 in an propagation of its sec funding round, VentureWire reports. Its angels included Atlas Venture, CDC Invention, Crocethia alba Ventures and Ventech.


The company tells it was set up in 2005 from the uniting of Xytis Pharmaceutics and Remergent. (Sounds more to me like Xytis got down Remergent, but they're free to draw it nevertheless they'd like.) Its lead drug campaigner, XY2405, blocks a cellular protein named the Bradykinin B2 receptor, a signal atom idea to further rubor.



Xytis is essaying the drug as a potential intervention for traumatic encephalon hurt; the speck is presently in mid-stage, phase II runs. The company is besides examination an antidepressant drug in early-stage tests.


Xytis embossed half the money last August, then standard the sec USD 7.5 000 000 in April, the company stated VentureWire. It has antecedently embossed USD 24.5 000 000 in its current avatar, and its "precursor society" drew in USD 6.5 000 000.


Symptomatic maker Sword lily Biotechnology plans to go public, launch breast-cancer test - Santa Claus Clara, Caliph.-based Lis Biotechs, a developer of molecular diagnostic tests, is setting up to go public, VentureWire reports. The company plans a little offer on the The Bulletin Board - if I'm meter reading its the SEC filing right, its existent shareowners will bring up about USD 1.1 000 000, with no take headed to the company - and hopes to launch a breast-cancer test posterior this twelvemonth.


Flag plans to apply fries to mensurate cistron action in breast malignant neoplastic disease, with the promise of anticipating the betting odds that a surgically distant neoplasm will repeat and, finally, portion affected roles and doctors customise malignant neoplastic disease intervention from an early stage. The company claims that it will be competitory with Genomic Wellness and Agendia, two companionship with like tests for calling breast-cancer return.


Tags:


Автор: на

Комментариев нет:

Отправить комментарий

Подписаться на: Комментарии к сообщению (Atom)